Hepatic complications of hematopoietic cell transplantation

Liver Immunology: Principles and Practice

Volumn , Issue , 2007, Pages 409-421

  Shulman, Howard M ^a   McDonald, George B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46349096819     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-518-3_32     Document Type: Chapter

References (92)

1. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005; 41:345-352.
2. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Blume K, Forman SJ, Appelbaum F, eds. Thomas' Hematopoietic Cell Transplantation, 3rd ed. Malden, MA: Blackwell Publishing, 2004:769-810.
3. Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In:Wingard JR, BowdenRA, eds. Management of Infection in Oncology Patients. London: Martin Dunitz, 2003: 321-342.
4. Deschenes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. Hepatology 2004; 39:867-868.
5. Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996; 62:1358-1360.
6. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624.
7. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection after bone marrow transplantation: A cohort study with 10 year follow-up. Hepatology 1999; 29:1893-1899.
8. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102:1578-1582.
9. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylateinduced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16:2160-2161.
10. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. Gastroenterol 2005; 39:75-77.
11. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients Blood 2004; 103:76-82.
12. Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: A cautionary tale. Blood 2002; 99:4245-4246.
13. Lau GK, He M-L, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36:702-709.
14. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840-844.
15. Anttila VJ, Lamminen AE, Bondestam S, et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56:82-87.
16. Donnelly JP. A strategy for managing fungal infections in haematopoietic stem cell transplantation. Transplant Infect Dis 2000; 2:88-95.
17. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
18. Wisell J, Boitnott J, Haas M, et al. Glycogen pseudo-ground glass change in hepatocytes. American J Surg Pathol 2006; 30: 1085-1090.
19. Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venocclusive disease) Semin Liver Dis 2002; 22:27-41.
20. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venocclusive disease of the liver after marrow transplantation: Histologic correlates of clinical signs and symptoms. Hepatology 1994; 19:1171-1180.
21. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101:2043-2048.
22. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102:1578-1582.
23. Bornhauser M, Storer B, Slattery J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102:820-826.
24. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
25. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015-1022.
26. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127:549-558.
27. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplant with severe venoocclusive disease and multi-system organ failure: Response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100:4337-4343.
28. McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005; 78:298-308.
29. Meresse V, Hartmann O, Vassal G, et al. Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992; 10:135-141.
30. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
31. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplant. Biology Blood Marrow Transplant 2007; 13: 206-217.
32. Stockschlaeder M, Storb R, Pepe M, et al. A pilot study of low dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992; 80:49-54.
33. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapyresistance modifier in acute leukemia J Clin Oncol 1993; 11:1652-1660.
34. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction following gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:4245-4246.
35. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-vs-host disease of the liver: Presentation as an acute hepatitis. Hepatology 2000; 32:1265-1271.
36. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graftversus- host disease after donor lymphocyte infusion. Blood 2002; 100:3903-3907.
37. Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WI, McDonald GB. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-1008.
38. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation. Hepatology 1988; 8:463-470.
39. Crawford JM. Graft-versus-host disease of the liver. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease, 2nd ed., New York: Marcel Dekker, 1997:315-336.
40. Snover DC, Weisdorf SA, Ramsay AK, McGlave P, Kersey JH. Hepatic graft-versushost disease: A study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4:123-130.
41. Nakanuma Y, Terada T, Ohtake S, Govindarajan S. Intrahepatic periductal glands in graft-versus-host disease. Acta Pathol Jpn 1988; 38:281-289.
42. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988; 167:1211-1227.
43. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson Jr. Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41:809-818.
44. Fujii N, Takenaka K, Shinagawa K, et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27:1007-1010.
45. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223-1230.
46. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93:3259-3266.
47. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104:595-603.
48. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features. Hepatology 1991; 13:882-891.
49. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31:792-799.
50. Stechschulte DJ Jr, Fishback JL, Emami A, Bhatai P. Secondary biliary cirrhosis as a consequence of graft-versus-host disease. Gastroenterology 1990; 98:223-225.
51. Leisenring W, Martin P, Petersdorf E, et al. An acute graft-versushost disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 108:749-755.
52. Hubscher SG, Buckels JA, Elias E, McMaster P, Neuberger J. Vanishing bile-duct syndrome following liver transplantation - is it reversible? Transplantation 1991; 51:1004-1010.
53. Lunz JG 3rd, Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: Increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathology 2001; 158:1379-1390.
54. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100:1977-1983.
55. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 1996; 111:193-198.
56. Ko CW, Murakami C, Sekijima JH, Kim MH, McDonald GB, Lee SP. Chemical composition of gallbladder sludge in patients after marrow transplantation. Am J Gastroenterol 1996; 91:1207-1210.
57. Jardines LA, O'Donnell MR, Johnson DL, Terz JJ, Forman SJ. Acalculous cholecystitis in bone marrow transplant patients. Cancer 1993; 71:354-358.
58. Ko CW, Gooley T, Schoch HG, et al. Acute pancreatitis in marrow transplant patients: Prevalence at autopsy and risk factor analysis. Bone Marrow Transplant 1997; 20:1081-1086.
59. Cabana MD, Alavi A, Berlin JA, Shea JA, Kim CK, Williams SV. Morphine-augmented hepatobiliary scintigraphy: A meta-analysis. Nucl Med Commun 1995; 16:1068-1071.
60. Murakami CS, Louie W, Chan GS, et al. Biliary obstruction in hematopoietic cell transplant recipients: An uncommon diagnosis with specific causes. Bone Marrow Transplant 1999; 23:921-927.
61. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome. Biolo of Blood Marrow Transplant 2000; 6:44-49.
62. Blanke C, Clark C, Broun ER, et al. Evolving pathogens in allogeneic bone marrow transplantation: Increased fatal adenoviral infections. Am J Med 1995; 99:326-328.
63. Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: Importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000; 25: 1003-1005.
64. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32:1290-1297.
65. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: A survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486.
66. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004; 23:583-588.
67. Shields AF, Hackman RC, Fife KH, Corey L, Meyer JD. Adenovirus infections in patients undergoing bone marrow transplantation. N Engl J Med 1985; 312:529-533.
68. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77:76-84.
69. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients. Medicine (Balti) 1998; 77:246-254.
70. Rossetti F, Brawner DL, Bowden RA, et al. Fungal liver infection in marrow transplant patients: Prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20:801-811.
71. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich 3)-beta-D-glucan?enzyme- linked immunosorbent assay for galactomannan, and a (1 - c test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733-2741.
72. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004; 190:641-649.
73. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infec Dis 2004; 39:199-205.
74. Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36:509-513.
75. Kornbluth AA, Danzig JB, Bernstein LH. Clostridium septicum infection and associated malignancy. Report of 2 cases and review of the literature. Medicine (Balti) 1989; 68:30-37.
76. Frere P, Canivet JL, Gennigens C, Rebeix JP, Fillet G, Beguin Y. Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2000; 26:343-345.
77. Filipovich A, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. I. Diagnosis of staging working group report. Biol Blood Marrow Transplant 2005; 11:945-955.
78. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graftversus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12:31-47.
79. Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116:624-629.
80. Shimizu T, Kasahara M, Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. N Engl J Med 2006; 354:1536-1537.
81. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103:1618-1624.
82. de Latour RP, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005; 36:709-713.
83. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327-331.
84. Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993; 342:1388-1391.
85. Tomas JF, Pinilla I, Garcia-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant 2000; 26:649-655.
86. Kamble R, Selby G, Mims M, Kharfan-Dabaja M, Ozer H, George J. Iron Overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:506-510.
87. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90:994-998.
88. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Medi 2002; 136:667-672.
89. Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22:521-524.
90. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19:464-471.
91. Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987; 43:35-40.
92. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med 2004; 350:2624-2625.